Site Logo
All articles
Commentary on News

Patient experiences: qualitative analysis of warfarin use

Evidano6 min read

This post explains what the PLOS One qualitative study found about day-to-day warfarin use after prosthetic valve surgery and how AI-enabled qualitative research accelerates action. The primary keyword is "qualitative analysis of warfarin use" and this post is written for qualitative researchers, clinical teams, and digital health product managers who need extractable quotes, dated statistics, and practical synthesis. According to the PLOS One article by Mgala et al. (2026), the study conducted 12 in-depth interviews at the Jakaya Kikwete Cardiac Institute between April and June 2025 and published results on 5 August 2026.

Key Takeaways

The core finding from the PLOS One study by Mgala et al. (2026) is that patients accept warfarin as life-saving but face daily diet, cost, monitoring, and mixed-counselling barriers that undermine adherence (PLOS One).

  • 12 participants were interviewed between April and June 2025, according to Mgala et al. (2026).
  • On 5 August 2026 Mgala et al. reported that only 3 of 12 participants had INR values within the therapeutic range while 6 were above and 3 were below the range (PLOS One, 2026).
  • Mgala et al. (2026) found 7 of 12 participants had no health insurance and 5 had insurance, and 5 participants reported prior thromboembolic events.
  • Mgala et al. (2026) recommend decentralizing INR testing, standardizing counselling, and using low-cost digital follow-up such as SMS or WhatsApp to improve continuity of care.

What happened and how the study was done

What happened: Mgala et al. (2026) performed an exploratory qualitative study at the Jakaya Kikwete Cardiac Institute, interviewing 12 patients about long-term warfarin use between April and June 2025.

According to Mgala et al. (2026), participants ranged in age from 30 to 66 years and included 7 females and 5 males, with duration of warfarin use from 10 months to 15 years.

According to Mgala et al. (2026), the research used purposive sampling to saturation, audio-recorded Kiswahili interviews, manual inductive-deductive content analysis, and member checking with four participants to validate findings.

According to Mgala et al. (2026), the hospital context included a 157-bed capacity and approximately 20 to 40 valve surgeries per month, which situates the sample within a national referral cardiac centre.

Findings snapshot

Date / EventMetricValueImplication
April–June 2025Interviews conductedn = 12 participantsQualitative sample reached saturation per authors (Mgala et al., 2026)
5 August 2026Publication datePLOS One article by Mgala et al. (2026)Peer-reviewed qualitative evidence available for implementation planning
At time of interviews (Apr–Jun 2025)INR distribution3 therapeutic, 3 sub-therapeutic, 6 supra-therapeuticHigh variability in anticoagulation control highlights monitoring gaps
At time of interviews (Apr–Jun 2025)Insurance coverage5 insured, 7 uninsuredOut-of-pocket costs constrained clinic attendance and medication access
Ongoing service contextJKCI throughput≈1, 800 outpatients and 100 inpatients weekly; 20–40 valve surgeries/monthCentralized services create geographic access barriers (Mgala et al., 2026)

Implications for qualitative analysis of warfarin use

Bottom line for researchers and implementers: Mgala et al. (2026) show that lived experience, not only clinical metrics, drives warfarin adherence and must be captured in implementation design.

  • For qualitative researchers: Mgala et al. (2026) used semi-structured Kiswahili interviews and combined inductive-deductive content analysis, meaning codebooks should preserve original-language transcripts before translation.
  • For clinical teams: Mgala et al. (2026) document contradictory counselling as a cause of harmful dose changes, so standardizing scripts and shared notes can reduce risk.
  • For digital health teams: Mgala et al. (2026) recommend low-cost interventions such as SMS reminders and WhatsApp coordination to address missed follow-ups and inconsistent counselling.

How Evidano Helps

Problem: fragmented qualitative data slows actionable insight

Evidano is an AI-powered qualitative data analysis platform that helps researchers analyze interviews, open-ended surveys, and documents.

Evidano maps raw transcripts to themes quickly so teams can find whether patient-reported barriers in a study like Mgala et al. (2026) are distributional or isolated.

Problem: manual coding loses language nuance

Solution: Evidano preserves original-language transcripts while supporting translation with custom dictionaries, which matches Mgala et al.'s practice of coding in Kiswahili then translating (Mgala et al., 2026).

See our features page for AI transcription and translation options: Evidano features.

Problem: connecting quotes to counts and segments is slow

Solution: Evidano generates thematic, frequency, and cross-segment analyses so teams can quantify statements like "only 3 of 12 had therapeutic INR" (Mgala et al., 2026) and extract the supporting participant quotes for reporting.

Solution: Evidano also supports secure data handling for sensitive qualitative datasets and audit trails for reproducible codebooks.

FAQ: qualitative analysis of warfarin use

How many patients did the PLOS One study interview and when was data collected?

Answer: The study interviewed 12 patients and collected data between April and June 2025, as reported by Mgala et al. (2026).

Supporting detail: Mgala et al. (2026) recruited participants by purposive sampling and confirmed saturation after ten interviews with two additional interviews for consistency.

What were the main day-to-day challenges patients reported about warfarin?

Answer: Patients reported restrictive dietary guidance, medication side effects, emotional stress, financial cost, inconsistent provider advice, and limited INR access, according to Mgala et al. (2026).

Supporting detail: Mgala et al. (2026) categorized findings into two themes: adapting to life with warfarin and navigating an unstructured continuum of care, and included direct participant quotations illustrating each challenge.

Can AI tools reproduce the coding approach used by Mgala et al. (2026)?

Answer: Yes, AI-assisted platforms can replicate an inductive-deductive coding workflow while preserving original-language nuances and codebook audit trails.

Supporting detail: Mgala et al. (2026) coded in Kiswahili then translated excerpts; Evidano's transcription and custom-translation support can automate transcription and preserve source-language codes for verification.

Which participant quotes best illustrate patient burdens in the study?

Answer: Representative quotes include dietary frustration, relief after surgery, and calls for free medication, as documented by Mgala et al. (2026).

Supporting detail and quotes: "… I was advised that one avocado per week is enough" (P03, Mgala et al., 2026); "Before, I couldn’t even walk... but after the valve replacement, I felt relieved" (P08, Mgala et al., 2026); and "the government should consider giving us these medications for free" (P02, Mgala et al., 2026).

Conclusion & Next Steps

This PLOS One qualitative study by Mgala et al. (2026) shows that improving warfarin outcomes requires addressing diet counselling, travel and cost barriers, inconsistent provider messaging, and decentralized INR testing.

For qualitative teams, the study is a model of language-preserving analysis: interviews in Kiswahili, manual coding, and member checking (Mgala et al., 2026).

If your team needs to scale thematic coding, link quotes to counts, and prepare reproducible codebooks from transcripts like those in Mgala et al. (2026), AI-assisted workflows can cut weeks of manual work.

Get started and test an AI-enabled qualitative workflow today: Try Evidano for free.

Topics

  • qualitative analysis of warfarin use
  • warfarin qualitative study
  • warfarin adherence Tanzania
  • INR monitoring qualitative

Keep reading

Browse all articles
Company
About
Newsletter

Product updates, research, and tips — straight to your inbox.

© Evidano, All Rights Reserved.